|
Malignant tumor of colon
|
0.040 |
Biomarker
|
disease |
BEFREE |
The tumor metastasis suppressor gene Drg-1 has been shown to suppress metastasis without affecting tumorigenicity in immunodeficient mouse models of prostate and colon cancer.
|
17178897 |
2006 |
|
Malignant tumor of colon
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
The Drg-1 gene has been shown to suppress tumor metastasis in animal models of prostate and colon cancer, and the expression of this gene is significantly reduced with advancement of prostate and breast cancers in clinical setting.
|
15520163 |
2004 |
|
Malignant tumor of colon
|
0.040 |
Biomarker
|
disease |
BEFREE |
On the other hand, we and others have demonstrated that the Drg-1 gene suppresses prostate and colon cancer metastases in mouse models.
|
15184886 |
2004 |
|
Malignant tumor of colon
|
0.040 |
Biomarker
|
disease |
BEFREE |
We propose that Drg-1 suppresses colon cancer metastasis by inducing colon cancer cell differentiation and partially reversing the metastatic phenotype.
|
10676663 |
2000 |
|
Colon Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
We propose that Drg-1 suppresses colon cancer metastasis by inducing colon cancer cell differentiation and partially reversing the metastatic phenotype.
|
10676663 |
2000 |
|
Colon Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
On the other hand, we and others have demonstrated that the Drg-1 gene suppresses prostate and colon cancer metastases in mouse models.
|
15184886 |
2004 |
|
Colon Carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
The Drg-1 gene has been shown to suppress tumor metastasis in animal models of prostate and colon cancer, and the expression of this gene is significantly reduced with advancement of prostate and breast cancers in clinical setting.
|
15520163 |
2004 |
|
Colon Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
The tumor metastasis suppressor gene Drg-1 has been shown to suppress metastasis without affecting tumorigenicity in immunodeficient mouse models of prostate and colon cancer.
|
17178897 |
2006 |
|
Malignant neoplasm of breast
|
0.030 |
Biomarker
|
disease |
BEFREE |
We have investigated protein kinase C (PKC) signaling, a putative differentiation-related and metastasis suppressor gene Cap43/NDRG1/Drg-1, and Y-box binding protein-1 (YB-1) to identify new molecular targeting for breast cancer.
|
18224398 |
2008 |
|
Malignant neoplasm of breast
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Consistent with these results, our immunohistochemical analysis revealed that PTEN expression correlates significantly with Drg-1 in both prostate and breast cancer cases.
|
15520163 |
2004 |
|
Malignant neoplasm of breast
|
0.030 |
Biomarker
|
disease |
BEFREE |
Together, our results strongly suggest functional involvement of the Drg-1 gene in suppressing the metastatic advancement of human breast cancer.
|
15184886 |
2004 |
|
Breast Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
We have investigated protein kinase C (PKC) signaling, a putative differentiation-related and metastasis suppressor gene Cap43/NDRG1/Drg-1, and Y-box binding protein-1 (YB-1) to identify new molecular targeting for breast cancer.
|
18224398 |
2008 |
|
Breast Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Together, our results strongly suggest functional involvement of the Drg-1 gene in suppressing the metastatic advancement of human breast cancer.
|
15184886 |
2004 |
|
Breast Carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Consistent with these results, our immunohistochemical analysis revealed that PTEN expression correlates significantly with Drg-1 in both prostate and breast cancer cases.
|
15520163 |
2004 |
|
Colorectal Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
These data demonstrate that SBP1 has tumor suppressor functions that are inhibited in colorectal cancer through epigenetic silencing.
|
19924303 |
2009 |
|
Colorectal Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
These data demonstrate that higher expression of SBP1 is associated with differentiation of the normal colonic epithelia and may be a positive prognostic factor for survival in stage III colorectal carcinoma.
|
18435490 |
2008 |
|
Malignant neoplasm of prostate
|
0.020 |
Biomarker
|
disease |
BEFREE |
To clarify the functional role of Drg-1 in prostate cancer, we examined a clinical archive of cancer specimens for the expression of Drg-1 by immunohistochemistry.
|
12702552 |
2003 |
|
Malignant neoplasm of prostate
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Our immunohistochemical analysis on prostate cancer specimens revealed that nuclear expression of ATF3 was inversely correlated to Drg-1 expression and positively correlated to metastases.
|
17178897 |
2006 |
|
Prostate carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
To clarify the functional role of Drg-1 in prostate cancer, we examined a clinical archive of cancer specimens for the expression of Drg-1 by immunohistochemistry.
|
12702552 |
2003 |
|
Prostate carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Our immunohistochemical analysis on prostate cancer specimens revealed that nuclear expression of ATF3 was inversely correlated to Drg-1 expression and positively correlated to metastases.
|
17178897 |
2006 |
|
Liver carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
The role of SBP1 in HCC was investigated using siRNA.
|
22512980 |
2012 |
|
Liver carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
SBP1 expression reduced HCC cell migration and invasion by inhibiting EMT.
|
30034941 |
2018 |
|
Malignant neoplasm of colon and/or rectum
|
0.020 |
Biomarker
|
disease |
BEFREE |
These data demonstrate that SBP1 has tumor suppressor functions that are inhibited in colorectal cancer through epigenetic silencing.
|
19924303 |
2009 |
|
Malignant neoplasm of colon and/or rectum
|
0.020 |
Biomarker
|
disease |
BEFREE |
We further characterized the role of SBP1 in colorectal cancer in vivo and in vitro.
|
18435490 |
2008 |
|
Benign Ovarian Neoplasm
|
0.010 |
Biomarker
|
disease |
BEFREE |
The percent of anti-SBP1-positive sera was higher in POF (P = 0.02), irregular ovulation (P = 0.001), unexplained causes (P = 0.02), late (III-IV)-stage OvCa (P = 0.02) but was not significant in endometriosis, benign ovarian tumors/cysts, early stage (I-II) OvCa or uterine cancer compared to healthy controls.
|
27965399 |
2017 |